A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
| Condition | Atopic Dermatitis |
|---|---|
| Phase | Phase 3 |
| Sponsor | Amgen |
| Status | Completed |
| Enrollment | 187 participants |
| Interventions | Rocatinlimab |
| Start date | Jan 30, 2023 |
| Completion date | Jul 31, 2025 |
| Results posted | Jul 24, 2026 |
Summary
The primary objective of this study is to describe the safety and tolerability of rocatinlimab in adolescents with moderate-to-severe AD.
Number of Participants Who Experienced Treatment-emergent Serious Adverse Events (TESAEs)
| Rocatinlimab | 4 Participants |
|---|
Open in BENITIONS View on ClinicalTrials.gov
Other trials for this condition
- A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moder — LEO Pharma
- A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis — Eli Lilly and Company
- Aquacel Hypersensitivity Dressing in TJAs — Rush University Medical Center
- A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE) — Amgen
- A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic D — Amgen
- BROadband vs Narrowband photoTherapy for Eczema Trial Nested in the CACTI Cohort — Women's College Hospital